RT journal article
T1 The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP)
A1 Velasco, Pablo
A1 Bautista, Francisco
A1 Rubio, Alba
A1 Aguilar, Yurena
A1 Rives, Susana
A1 Dapena, Jose L.
A1 Pérez, Antonio
A1 Ramirez, Manuel
A1 Saiz-Ladera, Cristina
A1 Izquierdo, Elisa
A1 Escudero, Adela
A1 Camós, Mireia
A1 Vega-García, Nerea
A1 Ortega, Margarita
A1 Hidalgo-Gómez, Gloria
A1 Palacio, Carlos
A1 Menéndez, Pablo
A1 Bueno, Clara
A1 Montero, Joan
A1 Romecín, Paola A.
A1 Zazo, Santiago
A1 Alvarez, Federico
A1 Parras, Juan
A1 Ortega-Sabater, Carmen
A1 Chulian García, Salvador
A1 Rosa Durán, María
A1 Cirillo, Davide
A1 García, Elena
A1 García, Jorge
A1 Manzano Muñoz, Albert
A1 Minguela, Alfredo
A1 Fuster, Jose L.
A2 Matemáticas
K1 artificial intelligence
K1 cancer registry
K1 functional assay
K1 precision medicine
K1 relapsed acute lymphoblastic leukemia
AB Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with survival rates exceeding 85%. However, 15% of patients will relapse; consequently, their survival rates decrease to below 50%. Therefore, several research and innovation studies are focusing on pediatric relapsed or refractory ALL (R/R ALL). Driven by this context and following the European strategic plan to implement precision medicine equitably, the Relapsed ALL Network (ReALLNet) was launched under the umbrella of SEHOP in 2021, aiming to connect bedside patient care with expert groups in R/R ALL in an interdisciplinary and multicentric network. To achieve this objective, a board consisting of experts in diagnosis, management, preclinical research, and clinical trials has been established. The requirements of treatment centers have been evaluated, and the available oncogenomic and functional study resources have been assessed and organized. A shipping platform has been developed to process samples requiring study derivation, and an integrated diagnostic committee has been established to report results. These biological data, as well as patient outcomes, are collected in a national registry. Additionally, samples from all patients are stored in a biobank. This comprehensive repository of data and samples is expected to foster an environment where preclinical researchers and data scientists can seek to meet the complex needs of this challenging population. This proof of concept aims to demonstrate that a network-based organization, such as that embodied by ReALLNet, provides the ideal niche for the equitable and efficient implementation of “what's next” in the management of children with R/R ALL. 2023 Velasco, Bautista, Rubio, Aguilar, Rives, Dapena, Pérez, Ramirez, Saiz-Ladera, Izquierdo, Escudero, Camós, Vega-Garcia, Ortega, Hidalgo-Gómez, Palacio, Menéndez, Bueno, Montero, Romecín, Zazo, Alvarez, Parras, Ortega-Sabater, Chulián, Rosa, Cirillo, García, García, Manzano-Muñoz, Minguela and Fuster.
PB Frontiers Media SA
SN 2296-2360
YR 2023
FD 2023
LK http://hdl.handle.net/10498/32280
UL http://hdl.handle.net/10498/32280
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 10-may-2026